On June 11, 2025, Entrada Therapeutics, Inc. held its Annual Meeting, where stockholders voted to elect three directors and ratified Ernst & Young LLP as the accounting firm for 2025, with 30,259,526 shares represented. The elected directors are Dipal Doshi, Kush M. Parmar, M.D., Ph.D., and Mary Thistle.